1 The EIC Accelerator Project

EIC Accelerator Program Overview

The EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support innovative small and medium-sized enterprises (SMEs) and startups with high growth potential and disruptive technologies. The program aims to bridge the gap between early-stage innovation and market deployment, specifically targeting the DeepTech sector. It provides a unique blend of funding opportunities, including grants and equity investments, to facilitate the commercialization of innovative products and services.

Funding Structure

The EIC Accelerator offers a funding mechanism that combines both grants and equity investments.

The EIC Accelerator's dual funding approach is designed to minimize financial risk for startups while incentivizing private sector investment. By providing substantial funding, the program helps innovative companies gain traction and accelerate their growth in competitive markets.

Purpose of the EIC Accelerator

The EIC Accelerator plays a pivotal role in the European DeepTech and startup ecosystem. Its primary purpose is to foster innovation by supporting SMEs and startups that possess groundbreaking technologies and solutions. By focusing on high-impact innovations, the program aims to enhance Europe's competitiveness in the global market.

The EIC Accelerator also serves as a catalyst for attracting private investment. By providing initial funding, it encourages venture capitalists and other investors to participate, thereby increasing the chances of successful commercialization. The program not only assists in scaling innovative businesses but also contributes to job creation and economic growth within the European Union.

Role in Scaling Companies

The EIC Accelerator supports companies in scaling their operations through a comprehensive approach that includes funding, coaching, and networking opportunities. By offering financial resources, the program enables startups to invest in technology development, enter new markets, and refine their business models.

Additionally, the EIC Accelerator provides business development support, including access to mentors and experts who can guide companies through the challenges of scaling. By fostering connections with industry leaders and potential investors, the program enhances the visibility of participating startups, increasing their likelihood of securing further funding from private sectors.

EIC Accelerator Winner: Alesi Surgical Ltd

Company Overview: Alesi Surgical Ltd is a UK-based company that specializes in innovative surgical technologies aimed at improving patient outcomes and enhancing surgical procedures.

Project Acronym: ePIPAC

Funding Type: Grant only

Website: alesi-surgical.com

Submission Date: October 5, 2022

Project Description: ePIPAC

The ePIPAC project focuses on the development of a novel minimally invasive surgical technology designed for the delivery of therapies directly into the abdominal cavity. This innovative approach targets patients suffering from peritoneal carcinomatosis—a condition where cancer spreads to the peritoneal cavity, making treatment particularly challenging.

The ePIPAC system utilizes a sophisticated combination of robotics and imaging technologies to facilitate precise and controlled delivery of chemotherapeutic agents. This method aims to improve drug efficacy while minimizing side effects associated with traditional systemic chemotherapy.

Technology Basics and Background

The underlying technology of ePIPAC is based on advanced robotics and minimally invasive surgical techniques. Alesi Surgical has developed a specialized platform that combines robotic assistance with real-time imaging, allowing surgeons to perform intricate procedures with enhanced precision.

The ePIPAC system involves the use of a specialized catheter designed to deliver high doses of chemotherapy directly into the peritoneal cavity. By targeting the tumor site directly, the system aims to increase the concentration of therapeutic agents at the tumor while reducing systemic exposure, thereby decreasing the likelihood of adverse effects.

This innovative approach not only improves treatment outcomes but also reduces recovery times for patients, contributing to overall enhanced healthcare efficiency. The project aligns with current trends in personalized medicine, highlighting the importance of tailored treatment strategies in oncology.

In summary, the EIC Accelerator program serves as a vital support mechanism for innovative companies like Alesi Surgical Ltd, enabling them to bring groundbreaking technologies such as ePIPAC to market. By combining grants and equity investments, the program enhances the scalability and sustainability of high-impact innovations within the European ecosystem.

2 The Funding Rounds

# Alesi Surgical Ltd: Funding Journey and Growth

Alesi Surgical Ltd, a Cardiff-based medical technology company from the United Kingdom, has established itself as a developer of innovative smoke management solutions for operating theaters. The company was selected for funding through the European Innovation Council (EIC) Accelerator program in the October 5, 2022 cut-off round.

EIC Accelerator Funding

Alesi Surgical was among 78 companies selected from over 1,000 applications in the highly competitive October 2022 EIC Accelerator call. This particular cut-off had a success rate of only 7.14%, with 240 companies reaching the interview stage and just 78 receiving funding approval.

The EIC Accelerator program offers several funding options: - Grant-only funding of up to €2.5 million (with a 70% funding rate)

• Blended finance (grant + equity)
• Grant-first funding
• Equity-only funding of up to €15 million

Based on the available information, Alesi Surgical applied for and was approved for a grant-only funding option through the EIC Accelerator program.

Total Funding History

Alesi Surgical has raised significant capital across multiple funding rounds:

• The company's most recent funding round was £5 million (approximately $6.4 million) in September 2024, led by Mercia Ventures with participation from existing investors IP Group and Panakès Partners
• According to the latest reports, Alesi Surgical has raised over £21 million (approximately $27 million) in total funding to date

Investor Information

The company has attracted investment from several notable investors: Current Investors:

• Mercia Ventures (lead investor in the September 2024 round)
• IP Group (existing investor)
• Panakès Partners (existing investor)

Company Background and Technology

Alesi Surgical is a spin-out from Cardiff University based at the Cardiff Medicentre with a team of approximately 15 people. The company has developed the Ultravision system, which uses electrical filtration to remove surgical smoke from operating theaters.

Their technology portfolio includes: - The first-generation Ultravision system for laparoscopic surgery (used in over 40,000 procedures)

• Ultravision2, an FDA-approved platform technology that can be integrated into surgical tools
• IonPencil, their newest FDA-approved product for routine surgery

Independent research has demonstrated that their system is 23 times more effective than alternative solutions at minimizing smoke release during laparoscopies and can capture and reduce the infectivity of viruses in surgical smoke.

Market Opportunity and Growth Strategy

The company is targeting a significant market opportunity with over 40 million smoke-producing surgical procedures performed annually in the USA, Europe, and Japan. With legislation requiring smoke management policies already passed in 18 US states and more expected to follow, Alesi is well-positioned in a growing regulatory-driven market.

The latest funding round will enable the company to: - Drive sales in the US market

• Seek regulatory approvals for its products in Europe and Japan
• Support overall business growth and expansion

Valuation and Exit Information

The search results do not provide specific information about Alesi Surgical's current valuation or any planned exit events such as IPO, buyouts, or acquisitions.

Sources: - EIC Accelerator 5 October cut-off - European Innovation Council

• Alesi Surgical company information, funding & investors | Dealroom.co
• EIC Accelerator winners and statistics October 2022 - Strata.team
• Alesi Raises £5M in Funding - FinSMEs
• Alesi Surgical secures £5 million Investment led by Mercia Ventures

3 The Press Releases

Alesi Surgical Ltd: Post-EIC Accelerator Funding Developments Alesi Surgical Ltd, a UK-based medical technology company, secured EIC Accelerator funding under the October 5, 2022 cut-off. The company qualified for a grant-only financing option, as confirmed by the European Innovation Council’s official list. While specific details of their awarded project (ePIPAC) remain limited in publicly available records, recent activity includes a September 2024 funding round, where Alesi raised £5M to advance its surgical smoke management technology.

Key Developments (2022–2024)

• EIC Accelerator Grant: Awarded grant-only funding for ePIPAC, though technical specifics of this project are not detailed in public EIC documentation.
• 2024 Funding Round: Raised £5M led by Mercia Ventures to scale its Ultravision system, an electrical filtration device designed to eliminate hazardous surgical smoke during laparoscopic procedures. The system has been utilized in over 40,000 surgeries globally as of September 2024.
• Technology Focus: Specializes in minimizing surgical smoke exposure—a critical innovation given the carcinogenic risks posed by conventional electrosurgical tools.

No partnerships, patents, or press releases from Alesi’s official website (alesi-surgical.com) were identified in available sources. Public updates focus primarily on their EIC selection and recent equity raise.

---

Sources

• EIC Accelerator 5 October cut-off
• Alesi Surgical raises funding to manage smoke created by surgical tools

4 The Technology Advancements

Alesi Surgical Ltd: Current Capabilities and Advancements

Alesi Surgical Ltd, based in the United Kingdom, is a leading innovator in minimally invasive surgery technologies, particularly known for its Ultravision system. This technology is designed to manage surgical smoke during laparoscopic and open surgeries, enhancing visibility and safety for surgeons and patients alike.

Current Capabilities

• Ultravision System: This advanced visualization system offers unparalleled surgical smoke control. It is approved for use in both laparoscopic and open surgeries, providing stable pneumoperitoneum with minimal patient CO2 exposure. The system includes tools like the Ionwand, 5mm Trocar, and integrated instruments, such as the IonPencil for open surgery and the Integrated L Hook for laparoscopic procedures.
• IonPencil: A revolutionary tool for open surgery, the IonPencil silently manages surgical smoke at the point of origin, eliminating the need for cumbersome smoke evacuators. It has received FDA clearance for use in open surgeries.

Advancements Since EIC Accelerator Funding

Following the EIC Accelerator funding in October 2022, Alesi Surgical has made significant strides in advancing its technology:

• Funding and Partnerships: In 2021, Alesi Surgical raised £9.4 million to support commercial and R&D objectives, including integrating Ultravision technology into energy-based instruments. This strategic move aimed to expand its distribution network and generate further clinical data.
• Ultravision2 System: The company launched the Ultravision2 system, which enhances performance, consistency, and usability. It also facilitates the development of integrated Ultravision instruments that combine tissue dissection with advanced smoke handling.
• Clinical Trials and Demonstrations: While specific details on new clinical trials since the funding are not readily available, Alesi Surgical's technology has been demonstrated to improve visibility and reduce procedural delays in laparoscopic surgeries, such as cholecystectomy.
• New Funding: In September 2024, Alesi Surgical secured an additional £5 million in funding to further enhance its surgical smoke management technology. This investment aims to expand its market presence and pursue regulatory approvals in Europe and Japan.

Technology Improvements

Alesi Surgical has continuously improved its technology to address health risks and workflow disruptions caused by surgical smoke. The Ultravision2 system is more effective in reducing surgical smoke compared to traditional methods, and it seamlessly integrates with existing surgical instruments.

Market Demonstrations and Clinical Studies

While specific new clinical trials or studies since the EIC funding are not detailed in available information, Alesi Surgical's technology has been praised by surgeons for its ability to maintain a clear visual field during procedures and reduce camera cleaning needs.

Patents and Scientific Publications

There is no specific information available on new patents filed or scientific studies published since the EIC funding. However, Alesi Surgical's advancements have been recognized for their potential to reshape surgical standards by improving safety and efficiency.

---

Sources: - Alesi Surgical - Ultravision Eliminate Surgical Smoke

• Ultravision Systems - Alesi Surgical
• Performance data - Alesi Surgical
• Ultravision2 - Alesi Surgical
• ALESI SURGICAL LIMITED overview - Companies House - GOV.UK
• ALESI SURGICAL RAISES £9.4M TO SUPPORT GROWTH
• Alesi Surgical Raises £5M for Advanced Surgical Smoke Management
• News - Alesi Surgical
• Alesi Surgical wins FDA clearance for IonPencil, lands new funding

5 The Partnerships and Customers

Alesi Surgical Ltd: Partnerships and Growth Since Receiving EIC Accelerator Funding

Alesi Surgical Ltd, a UK-based company specializing in innovative surgical smoke management technologies, received the EIC Accelerator funding in October 2022. This funding has positioned the company for significant growth and expansion in the global medical device market. Here's an overview of Alesi Surgical's partnerships, new relationships, and how these developments will impact their market position and technological advancements.

Partnerships and Customers

Alesi Surgical has established strategic partnerships with several key entities:

• Olympus Corporation: Alesi Surgical has an exclusive distribution agreement with Olympus for the Ultravision surgical smoke management system in the U.S.. This partnership enhances Alesi's reach and credibility in the American market.
• Investors: The company's investors include Mercia Ventures, IP Group, Panakès Partners, and Norgine Ventures. These partnerships have been crucial in securing funding for growth and development.
• Razan Medical Trading: Alesi Surgical is partnered with Razan Medical Trading, which supports its presence in international markets such as the Middle East.

New Partners and Customers

While specific new partners or customers since the EIC funding were not detailed, Alesi Surgical's ongoing partnerships and recent investments suggest a continued expansion strategy:

Mercia Ventures: The latest £5 million investment round was led by Mercia Ventures, marking a new partnership that will support Alesi's growth in the U.S. market.

Nature of New Relationships and Purpose

New relationships, such as the one with Mercia Ventures, focus on leveraging investment to drive market expansion and regulatory approvals in Europe and Japan. These partnerships aim to capitalize on the growing need for effective smoke management solutions in surgical environments, driven by emerging regulations in the U.S. and elsewhere.

Market Position and Technological Advancements

Alesi Surgical's relationships will significantly enhance its market position by:

• Scaling Technology: The company's Ultravision2 system, approved for both laparoscopic and open surgery, offers advanced smoke management capabilities. This technology benefits from partnerships that facilitate broader adoption and further innovation.
• Market Expansion: With increased investment and partnerships, Alesi Surgical is poised to expand its presence in major markets like the U.S., Europe, and Japan, leveraging its FDA-approved products to meet growing regulatory demands.

In summary, Alesi Surgical's partnerships have been instrumental in driving technological advancements and scaling its operations. The company's focus on innovative smoke management solutions positions it strongly in the medical device sector.

Sources:

• Alesi Surgical secures £5 million Investment led by Mercia Ventures
• Alesi Surgical Strikes Exclusive Deal With Olympus For Distribution
• ALESI SURGICAL RAISES £9.4M TO SUPPORT GROWTH
• News - Alesi Surgical
• Ultravision Systems - Alesi Surgical

6 The Hiring and Company Growth

Alesi Surgical Ltd: Team Growth and Strategic Expansion Post-EIC Accelerator Funding Since securing EIC Accelerator funding in October 2022, Alesi Surgical has focused on scaling its operations to meet growing demand for its surgical smoke management technology. While exact headcount figures remain undisclosed, the company’s leadership structure and recent milestones provide insights into its growth trajectory.

Key Developments in Team Dynamics

• Leadership Stability: The executive team, including CEO Dominic Griffiths and Chairman Phil Cooper, remains unchanged, with Todd Usen serving as Non-Executive Director. Their combined expertise in medical device commercialization positions Alesi to navigate regulatory landscapes and market expansion.
• Recent FDA Clearances: In August 2024, Alesi secured FDA clearance for its IonPencil electrosurgical device, followed by an additional open-surgery system approval in September 2024. These milestones likely necessitated expanded R&D and regulatory teams.
• Regulatory-Driven Hiring: With surgical smoke management now legislated in 18 U.S. states (up from one state in 2018), Alesi’s commercial and compliance teams are expected to grow to address increasing adoption requirements.

Strategic Hiring Implications
While specific new roles are not publicly listed, recent product launches suggest increased focus on:

The company’s emphasis on electrostatic precipitation technology positions it competitively within the $2.47B powered surgical instruments market (projected to reach $3.11B by 2029), requiring sustained investment in technical talent.

---

Sources

• Performance data - Alesi Surgical
• Alesi Surgical - Ultravision Eliminate Surgical Smoke
• Ultravision2 - Alesi Surgical
• Alesi Surgical secures FDA clearance for its revolutionary open...
• Our people - Alesi Surgical

FURTHER CITATIONS FROM SEARCH RESULTS: -How surgical smoke management can help patients and physicians -Powered Surgical Instruments Global Market Report 2025

7 The Media Features and Publications

Alesi Surgical Ltd: Post-EIC Accelerator Funding Developments

Alesi Surgical Ltd, a UK-based company specializing in surgical smoke management, received EIC Accelerator funding in October 2022. Since then, the company has made significant progress in developing and commercializing its innovative products.

Media Features and Publications

Alesi Surgical has gained attention in various media outlets and publications due to its cutting-edge technology in managing surgical smoke. The company's Ultravision system and IonPencil have been highlighted for their ability to improve visibility and safety during surgical procedures. Notable publications include UK Tech News, Medical Design & Outsourcing, and CtOl Digital, which have covered the company's advancements in smoke management technology and its recent funding achievements.

Content from Publications

Publications have emphasized Alesi Surgical's innovative approach to surgical smoke management. For instance, the company's technology is noted for being 23 times more effective than current solutions in reducing surgical smoke, enhancing both patient care and surgical efficiency. The FDA clearance for the IonPencil has also been highlighted as a significant milestone, enabling the company to expand its market reach.

Podcasts or Interviews

There is no specific information available about podcasts or interviews featuring the team of Alesi Surgical. However, the company's CEO, Dominic Griffiths, has been quoted in several articles discussing the company's growth and product developments.

Conference and Fair Visits, Presentations

While specific details about Alesi Surgical's participation in conferences and fairs are not readily available, the company's focus on expanding its presence in the US market and pursuing regulatory approvals in Europe and Japan suggests potential future involvement in international medical conferences.

Involvement in Events

Alesi Surgical's involvement in events is primarily driven by its efforts to commercialize its products and comply with increasing regulatory demands for smoke management in surgical settings. The company's contribution to improving surgical safety and efficiency positions it as a potential participant in medical industry events focused on innovation and safety standards.

Sources

• Alesi Surgical
• Alesi raises £5m to cut risk of surgical smoke in operating theatres
• Alesi Surgical secures £5 million Investment led by Mercia Ventures
• Contact us - Alesi Surgical
• Alesi Surgical Raises £5M for Advanced Surgical Smoke Management
• How surgical smoke management can help patients and physicians